Genovis: Bull Story, Fair Price - Redeye

Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst. We consider the cutting-edge enzyme producer well positioned for growth and see the current share price at an attractive level for a rapidly expanding compounder with compelling optionality.

Länk till analysen i sin helhet: https://www.redeye.se/research/868321/genovis-bull-story-fair-price?utm_source=finwire&utm_medium=RSS